首页> 外文期刊>Journal of population therapeutics and clinical pharmacology >Personalized Benefit-Harm Information Influences Patient Decisions Regarding Warfarin
【24h】

Personalized Benefit-Harm Information Influences Patient Decisions Regarding Warfarin

机译:个性化的福利信息影响患者对华法林的决定

获取原文
           

摘要

Background Providing information tailored to an individual patient's potential for benefit and harm, sufficient to allow for informed decision-making, is both time consuming and complicated. Objective We sought to determine whether presentation of different levels of personalization of chances of benefit and harm would influence patient decisions regarding warfarin treatment for atrial fibrillation (AF). Methods Randomized sequence study recruited participants 55 years or older who were at risk for atrial fibrillation but not currently taking warfarin. Using a standardized decision aid, patients considered 5 scenarios involving 3 levels of personalization (average, individualized, and individualized combined). The primary outcome was the simulated decision whether or not to take warfarin. Secondary outcomes included decisional conflict, factors influencing the decision and preferences for decision-making involvement. Results 71 of 75 patients randomized (mean age 69.8 yr, 50.7% female) completed the study. Compared with the presentation of average risks of benefit and harm, the tailored information by clinical prediction rule or by combined benefit-harm scenarios caused a significant change in the decision to take warfarin (p<0.0001). Presentation of the competing risk of death with and without treatment also had a significant effect on treatment choice (p<0.0001). At most, 46 (64.8%) reported being willing to take warfarin. Mean decisional conflict between presentation types did not differ, but patients rated the combined benefit-harm presentation as the most helpful (p = 0.04). Conclusion Information tailored towards individual chances of benefit and harm, although more complex, is preferred by patients and can change treatment decisions.
机译:背景技术提供针对个体患者的潜在利弊的信息既耗时又复杂,既足以进行明智的决策。目的我们试图确定呈现不同程度的受益和伤害机会的个性化设置是否会影响患者对华法林治疗房颤的决定。方法随机序列研究招募了55岁或55岁以上有房颤风险但目前不服用华法林的参与者。使用标准化的决策辅助工具,患者考虑了5个场景,涉及3个级别的个性化(平均,个性化和个性化组合)。主要结果是是否服用华法林的模拟决定。次要结果包括决策冲突,影响决策的因素以及参与决策的偏好。结果随机抽取75例患者(平均年龄69.8岁,女性50.7%)中的71例完成了研究。与平均利益和危害风险的表述相比,根据临床预测规则或组合的利益-危害情景定制的信息导致服用华法林的决定发生了重大变化(p <0.0001)。不论有无治疗,死亡竞争风险的表现也对治疗选择产生了显着影响(p <0.0001)。最多有46人(64.8%)表示愿意服用华法林。两种表现形式之间的平均决策冲突没有差异,但患者将综合的利弊组合评为最有帮助的(p = 0.04)。结论针对个人的受益和伤害机会量身定制的信息尽管更为复杂,但仍为患者偏爱,并可以改变治疗决策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号